Exavir Therapeutics receives $3 million award from NIH / NIAID to advance ultra-long-acting integrase inhibitor XVIR-110

Posted on August 22, 2023 (August 22, 2023) by [email protected]

$3M award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institute of Health (NIH), will support the development of XVIR-110